Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 8.62 B
The data is delayed by 15 minutes.
JAZZ is in the medium-term down -24% below S&P in 1 year.
Description: Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||60.49 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||6.21%||Sales Growth - Q/Q||-5.74%||P/E|
|P/E To EPS Growth||P/S||6.97||P/BV||6.6||Price/Cash Per Share|
|Price/Free Cash Flow||23.32||ROA||6.85%||ROE||16.99%||ROI||8.26%|
|Current Ratio||5||Quick Ratio||4.86||Long Term Debt/Equity||1.51||Debt Ratio||0.17|
|Gross Margin||90.71%||Operating Margin||30.68%||Net Profit Margin||17.95%||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||-3.26 M||Cash From Operating Activities||18.29 M||Gross Profit||281.01 M|
|Net Profit||96.56 M||Operating Profit||116.76 M||Total Assets||3.24 B||Total Current Assets||1.1 B|
|Total Current Liabilities||220.58 M||Total Debt||1.33 B||Total Liabilities||1.93 B||Total Revenue||309.3 M|
|High 52 week||183.18||Low 52 week||115.94||Last close||131.05||Last change||0.05%|
|RSI||30||Average true range||3.79||Beta||1.33||Volume||518.32 K|
|Simple moving average 20 days||-3.6%||Simple moving average 50 days||-2.76%||Simple moving average 200 days||-11.5%|
|Performance Week||4.03%||Performance Month||-6.49%||Performance Quart||5.06%||Performance Half||-13.91%|
|Performance Year||-14.95%||Performance Year-to-date||5.72%||Volatility daily||1.98%||Volatility weekly||4.42%|
|Volatility monthly||9.07%||Volatility yearly||31.41%||Relative Volume||302.29%||Average Volume||648.84 K|
|New High||New Low|
2019-06-18 09:45:01 | Jazz's JAZZ New Sleep Drug Sunosi Gets Schedule IV Status
2019-06-18 08:02:10 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-06-17 08:00:00 | Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ solriamfetol
2019-06-14 09:10:01 | Should Value Investors Buy Jazz Pharmaceuticals JAZZ Stock?
2019-06-13 08:01:55 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-06-11 08:02:20 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-06-10 08:02:05 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-06-08 08:02:53 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-06-06 12:23:46 | Should You Worry About Jazz Pharmaceuticals plc's NASDAQ:JAZZ CEO Pay?
2019-06-06 09:31:01 | Why Is Jazz JAZZ Down 7.3% Since Last Earnings Report?
2019-06-06 08:02:59 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-06-05 09:30:01 | JAZZ or ZTS: Which Is the Better Value Stock Right Now?
2019-06-04 08:02:06 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-05-28 09:36:01 | Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
2019-05-27 08:45:12 | Is Jazz JAZZ a Solid Growth Stock? 3 Reasons to Think " Yes "
2019-05-24 09:16:01 | 5 Best PEG Stocks Suitable for GARP Investors
2019-05-21 09:02:45 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-05-20 09:30:01 | JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
2019-05-17 09:10:01 | Is Jazz Pharmaceuticals JAZZ Stock Undervalued Right Now?
2019-05-10 09:55:01 | 3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
2019-05-10 08:45:12 | 3 Reasons Why Growth Investors Shouldn't Overlook Jazz JAZZ
2019-05-09 08:00:00 | Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
2019-05-08 08:01:12 | Jazz Pharma JAZZ Q1 Earnings and Sales Beat Estimates
2019-05-08 06:00:00 | Jazz Pharmaceuticals Hits All the Right Notes in Q1
2019-05-08 03:57:26 | Edited Transcript of JAZZ earnings conference call or presentation 7-May-19 8:30pm GMT
2019-05-08 01:24:19 | Jazz Pharmaceuticals JAZZ Q1 2019 Earnings Call Transcript
2019-05-07 19:35:11 | Jazz Pharmaceuticals JAZZ Beats Q1 Earnings and Revenue Estimates
2019-05-07 18:29:56 | Jazz: 1Q Earnings Snapshot
2019-05-07 16:05:00 | Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
2019-05-07 13:07:13 | 5 Stocks With Low Price-Earnings Ratios
2019-05-07 08:04:36 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-05-06 16:05:00 | Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
2019-05-02 09:30:01 | JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
2019-04-30 10:32:02 | Jazz Pharmaceuticals JAZZ Reports Next Week: Wall Street Expects Earnings Growth
2019-04-30 08:02:20 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-04-29 09:15:01 | Zoetis ZTS Hits Fresh High: Is There Still Room to Run?
2019-04-23 16:05:00 | Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019
2019-04-18 20:05:05 | Are Hedge Funds Right About Jazz Pharmaceuticals?
2019-04-16 09:30:01 | JAZZ vs. ZTS: Which Stock Is the Better Value Option?
2019-04-16 08:47:07 | Should We Be Cautious About Jazz Pharmaceuticals plc's NASDAQ:JAZZ ROE Of 16%?
2019-04-16 08:45:12 | 3 Reasons Why Jazz JAZZ Is a Great Growth Stock
2019-04-11 09:46:01 | Concert Pharma Initiates Early-Stage Schizophrenia Study
2019-04-09 10:46:50 | See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
2019-04-04 10:34:00 | Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations